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The HIV-1 late domain-2 S40A 
polymorphism in antiretroviral (or 
ART)-exposed individuals influences protease 
inhibitor susceptibility
Susan M. Watanabe1, Viviana Simon2, Natasha D. Durham3, Brittney R. Kemp4, Satoshi Machihara4, 
Kimdar Sherefa Kemal5, Binshan Shi6, Brian Foley7, Hongru Li3, Benjamin K. Chen3, Barbara Weiser8,9, 
Harold Burger8,9, Kathryn Anastos5, Chaoping Chen4* and Carol A. Carter1*
Abstract 
Background: The p6 region of the HIV-1 structural precursor polyprotein, Gag, contains two motifs, P7TAP11 and 
L35YPLXSL41, designated as late (L) domain-1 and -2, respectively. These motifs bind the ESCRT-I factor Tsg101 and the 
ESCRT adaptor Alix, respectively, and are critical for efficient budding of virus particles from the plasma membrane. 
L domain-2 is thought to be functionally redundant to PTAP. To identify possible other functions of L domain-2, we 
examined this motif in dominant viruses that emerged in a group of 14 women who had detectable levels of HIV-1 in 
both plasma and genital tract despite a history of current or previous antiretroviral therapy.
Results: Remarkably, variants possessing mutations or rare polymorphisms in the highly conserved L domain-2 were 
identified in seven of these women. A mutation in a conserved residue (S40A) that does not reduce Gag interaction 
with Alix and therefore did not reduce budding efficiency was further investigated. This mutation causes a simultane-
ous change in the Pol reading frame but exhibits little deficiency in Gag processing and virion maturation. Whether 
introduced into the HIV-1 NL4-3 strain genome or a model protease (PR) precursor, S40A reduced production of 
mature PR. This same mutation also led to high level detection of two extended forms of PR that were fairly stable 
compared to the WT in the presence of IDV at various concentrations; one of the extended forms was effective in 
trans processing even at micromolar IDV.
Conclusions: Our results indicate that L domain-2, considered redundant in vitro, can undergo mutations in vivo that 
significantly alter PR function. These may contribute fitness benefits in both the absence and presence of PR inhibitor.
Keywords: HIV Gag, HIV protease, Protease inhibitors, Late domain, Anti-retroviral drugs, ESCRT
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(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
As HIV-1 evolves in infected individuals, genetic changes 
can alter the way the virus replicates, leading to lower 
replication rates, persistence and latency or, alternatively, 
higher replication rates and progressive disease. Muta-
tions that confer resistance to protease (PR) inhibitors 
(PIs) are often accompanied by compensatory mutations 
in the gag gene at the PR cleavage sites in the encoded 
Gag substrate [1–4]. Mutations within the p6 region of 
Gag have also been linked to resistance [5–11], however, 
with the exception of a recent report [12], the evidence to 
date has been mainly correlative. The p6 region harbors 
determinants of viral budding; productive PR cleavages 
that ultimately lead to release of infectious particles are 
spatially and temporally linked to viral budding. Budding 
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is directed by two motifs in p6 designated as the late (L) 
domains: The P7(T/S)AP motif (L domain-1) binds the 
ESCRT-I component Tsg101 [(ESCRT, endosomal sort-
ing complex required for transport); [13–15]; reviewed 
in  [16]. The L35YPL(A/T/V/other)SL motif (L domain-2) 
binds the ESCRT adaptor protein Alix ([17–19]; reviewed 
in [20]). L domain-2 is thought to have a secondary 
redundant function when L domain-1 is intact because 
(1), all natural variants of the virus conserve PTAP while 
HIV subtype C lacks Y36, a major determinant of Alix 
binding and (2), mutations in PTAP impair virus release 
to a significant extent while the impact of LYPLXSL 
mutation is cell type-dependent.
We examined HIV-1 variants from 14 HIV-1 infected 
women with detectable HIV in both the genital tract 
and the plasma compartment despite a history of cur-
rent or past antiretroviral therapy (ART). Eleven women 
reported receiving ART at the time point studied and 
three had been treated previously. We found, surpris-
ingly, that half of the study participants harbored viruses 
that had mutations in L domain-2. Two substitutions that 
occurred at the same residue, S40F and S40A, were fur-
ther investigated by engineering the individual substitu-
tions into an HIV genome (pNL4-3). The substitution of 
F (S40F), where TCC = S to TTC = F, does not alter the 
sequence of the overlapping pol frame (TTC = F in the 
WT to TTT = F) but had an impact on several aspects 
of gag function [21–25]. The alanine (A) substitution 
(S40A), where TCC =  S to GCC =  A, in contrast, had 
a less deleterious effect on Gag processing, polyubiquit-
ination or particle maturation morphology but altered 
the sequence at the p6*/PR cleavage site in the overlap-
ping pol frame. In the wild type, the p6* reading frame 
ends with GTVSFNF/(N may be S, due to a natural poly-
morphism in subtype B); PR begins with\PQITLWQ. The 
S40A change in the gag frame is accompanied by an F to 
C change at the N-terminus of PR in the overlapping pol 
frame resulting in GTVSFN (or S) C/PQITLWQ. In the 
context of the NL4-3 strain of HIV-1, S40A altered sen-
sitivity to the protease (PR) inhibitor Indinavir (IDV). In 
the context of a model precursor, the mutation inhibited 
mature PR liberation but produced extended PR forms 
with autoproteolytic activity that resisted IDV treatment. 
Thus, our investigation suggests that L domain-2, consid-
ered redundant in  vitro, can evolve during disease pro-
gression to significantly alter PR function and contribute 
to viral fitness in both genital tract and plasma in vivo.
Results
Polymorphisms* in L domain‑2 of HIV‑1 variants 
from infected individuals
Kemal et  al. [26] investigated 14 women with detect-
able levels of HIV-1 RNA in both the genital tract and 
plasma despite a history of current or previous antiret-
roviral therapy (ART). RNA sequences were obtained 
for the region extending from the beginning of the pol 
frame through the end of the RT gene from a total of 
280 unique viral variants and then resistance genotypes 
(Virtual Phenotype; Virco BVBA) were determined for 
each variant. As the 5′ end of the pol frame overlaps the 
3′ end of gag that encodes the L domain-2, we translated 
the sequences (GenBank accession numbers DQ372126-
DQ372434) to obtain the Gag p6 region (in most cases, 
amino acids 10–52 of p6) and used this information to 
determine whether known viral drug resistance muta-
tions were accompanied by mutations in L domain-2 
that might have compensatory effects on viral fitness. 
Of the 14 women whose viral genomes were analyzed by 
sequencing individual variants, 7 displayed variants with 
L domain-2 changes. Table 1 shows the virologic, immu-
nologic, and clinical history of the participants with vari-
ants encoding L domain-2 changes (based on comparison 
to the subtype B consensus sequence). In addition, 15 
of 101 participants with persistent viremia displayed L 
domain-2 mutations detected by population sequencing 
of HIV-1 in plasma despite a history of ≥18 consecutive 
months of HAART (Highly Active ART; Kemal, Burger 
and Weiser, unpublished observations). Changes at L 
domain-2 sites L35, Y36 and L38 were previously shown 
to inhibit Alix binding and Alix-dependent budding 
[18, 19, 27]. Changes at S40, in contrast, increased Alix 
binding without apparent effect on budding efficiency 
[22]. Irrespective of the impact of the mutation on bud-
ding, the women who had the L domain-2 mutations had 
higher plasma HIV-1 RNA loads than those who did not 
(on average, 5.1 vs. 4.3 log10; [26]). Although the lack of 
response to ART and/or PIs in these particular women 
may be circumstantial, we considered the mutations wor-
thy of further investigation as they could have an effect 
in  vivo even if they were not the cause of the virologic 
failure of ART in these women.
[*As the parental sequence of the variants amplified 
from the clinical specimens is unknown, we defined here 
a polymorphism as a sequence variation identified in the 
Los Alamos National Laboratory (LANL) database at 
a frequency of at least 1 %. If the frequency is <1 %, the 
variation is regarded as a mutation.]
Remarkably, the L domain-2 mutation S40A was 
observed more frequently in the WIHS participants 
than the S40F change. S40A was identified in 27/27 sin-
gle genome variants amplified from genital tract and 
plasma specimens taken at a single visit and in 5 unre-
lated participants whereas S40F was detected in 2/28 
variants in only 1 participant. An examination of the 
HIV-1 sequences obtained from the other participants 
with variants encoding the S40A polymorphism revealed 
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that the substitution of A for S40 was the result of iden-
tical mutations. We considered the possibility that vari-
ants with the Gag p6 S40A polymorphism mutation 
were related, i.e., through a “founder” virus circulating in 
the NY area (the location of two of the study sites). This 
notion is very unlikely; although Ser can be encoded by 
TCN plus AG(C/T) (i.e., by six possible codons) and by a 
relatively common transition mutation like TCC to TCT, 
the TCC codon encoding Ser 40 in Gag p6 is nearly per-
fectly conserved not only in all subtypes of the HIV-1 M 
group, but also in the SIV-Chimpanzee, HIV-1 N group, 
HIV-1 O group, HIV-1 P group and SIV-Gorilla. This 
suggests that a strong selection pressure maintained the 
Gag p6 S40 to A mutation in the study population. Anal-
ysis using the Clustal W program [28], indicates that the 
viral genomes isolated from unrelated study participants 
were all subtype B but were not phylogenetically identi-
cal to each other or to other variants found in the LANL 
HIV sequence database (Fig.  1). Highlighted in blue are 
the sequences isolated from participant #36; highlighted 
in red are the sequences isolated from additional WIHS 
participants with HIV sequences with the S40A polymor-
phism. In one branch of the tree, a Thailand sequence 
falls within the cluster of WIHS sequences. This obser-
vation further supports our conclusion that the vari-
ants did not derive from a local geographical cluster or 
reflect recent ancestry (although we cannot eliminate this 
possibility).
The S40A mutation in Gag alters the amino acid sequence 
at the p6*‑PR cleavage site in the overlapping pol frame
In the infected cell, HIV-1 PR is initially synthesized as 
part of the Gag-Pol precursor polyprotein ([29]; reviewed 
in [30]). At the late stage of the replication cycle and con-
comitant with budding, the embedded protease domain 
is released through poorly understood auto-processing 
events and goes on to catalyze cleavage reactions critical 
to production of the infectious virus particle. As noted 
above, the S40F mutation does not alter the sequence of 
the overlapping pol frame while the S40A change causes 
a radical change at the N-terminal PR cleavage site 
encoded in the overlapping pol frame, the substitution of 
C for F56 (Fig. 2). This strongly suggests that the Gag p6 
S40A/Pol p6*-PR F56C mutation was selected and main-
tained in the quasispecies in the infected participants, 
possibly because these changes conferred a replicative 
advantage in the presence of PR inhibitors.
Mutation of S40 to Ala (S40A) has little apparent effect 
on virus budding, maturation, or infectivity
As previously reported by ourselves and others, the 
S40F polymorphism does not inhibit virus budding but 
affects several other aspects of viral replication, including 
Gag processing, maturation and infectivity [21–24]. The 
S40A and S40F mutations were engineered into an HIV 
genome (pNL4-3) and the viral particles produced by 
transfected cells were examined (Fig. 3). The substitution 
of Ala instead of Phe permitted almost WT-level forma-
tion of mature particles, as indicated by electron micros-
copy (panels A-C, F), and MAGI assays (panel E). Particle 
Fig. 1 Phylogeny of HIV-1 variants with A substituted for S at residue 
40. Sequences from WIHS variants 0915-9 and 1664-2 (GenBank 
accession number KU174531 and KU174530, respectively, Brooklyn NY 
site) and 1047-5 and 1066-5 (KU174533 and KU174532, respectively, 
Bronx NY site) were compared to HIV sequences from participant #36 
(Table 1; [26]). The phylogenetic tree compares 60 contemporaneous 
HIV subtype B sequences (black font) to the HIV sequences isolated 
from WIHS participants in Bronx and Brooklyn, NY (red font) and 
participant #36 (blue font)
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release formation was comparable, as indicated by ELISA 
(panel D). As reported previously, the substitution of Ala 
restored processing of CA-SP1 almost completely [22]. 
Since the substitution of Ala alters the PR, we can con-
clude that the altered PR can cleave CA-SP1, permitting 
virus maturation, and is responsible for the maintaining 
of the infectivity in the S40A variant.
The S40A mutation in NL4‑3 alters PI sensitivity
To begin to understand the nature of the potential repli-
cative advantage conferred by the S40A [gag frame]/F56C 
[pol frame] polymorphism, the replication of the  S40A 
mutant was examined in the absence and presence of PI 
(Fig. 4). Indinavir (IDV) and Saquinavir (SQV) were PIs 
employed in the WIHS cohort; IDV was used for our 
investigation as a study comparing the relative efficacies 
of SQV, IDV and Ritonavir (RTV), with respect to one-
year mean changes in HIV RNA plasma concentrations 
and CD4 cells counts, found no significant differences in 
their effectiveness [31]. When the baseline infectivity of 
S40A and the parental virus was matched (panel A), the 
a LYPLTS40L   
p6
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PTAP   
MA CA NC
gag  
pol  
b WT 
TTC CCT
L  Y P L T S L
V S F N F/ P Q I T 
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TGC CCT
GC/C
TGC CCT
Fig. 2 The S40A mutation in Gag alters the amino acid sequence at 
the p6*-PR cleavage site in the overlapping pol frame. a Schematic 
drawing of HIV-1 gag, pol gene organization showing the region of 
overlap. The C-terminal region of the gag gene encodes L domain-1 
(P7TAP10) and L domain-2 (35LYPLTSL41). Residue S40 in the latter 
motif is highlighted. This region of gag overlaps with the N-terminal 
region of the pol gene that encodes the N-terminal cleavage site of 
PR (SFSF56/PQIT). b The substitution of A for S40 in the gag reading 
frame (red font) alters the sequence encoding the N-terminus of PR 
in the pol reading frame (blue font). p6 S40A is Gag S488A (HXB2 
numbering)
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Fig. 3 Mutation of S40 to Ala minimally affects virus budding, maturation, or infectivity. a–c Electron microscopy of particles associated with cells 
transfected with pEnv and pNL4-3ΔEnv-WT (a), -S40A (b), or -S40F (c). Particle exhibiting mature morphology were quantified compared to WT 
(f). d p24 capsid antigen detected in culture media, as indicated by triplicate ELISA; e Viral particle infectivity, determined by MAGI assay, done in 
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the S40A mutant was found to exhibit threefold greater 
resistance to 0.01 μM IDV compared to the WT (panel 
B). At higher IDV concentrations, no resistance was 
detected.
We then reasoned that perhaps replicative advantage 
is conferred when the S40A is combined with other drug 
resistance mutations in PR. Previous studies suggested 
that several residues within PR but outside the active 
site modulate the conformation of the catalytic pocket 
[32]. Moreover, covariance analysis indicated that F56C/
L63P is a covarying pair existing at a low percentage in 
the drug-naïve population in LANL [33]. Strikingly, L63P 
and other L63 substitutions were apparent in every vari-
ant bearing the S40A mutation. L63P is a common poly-
morphism, however, its frequency was found to increase 
in PR inhibitor-treated patients [34]. It does not con-
fer resistance by itself, however, its emergence has been 
linked to poor or intermittent adherence [35]. We there-
fore examined the effect of L63 variants on drug sensi-
tivity. For these studies, we combined the most radical of 
these substitutions, L63P, with the S40A/F56C mutation 
forming F56C/L63P. As shown in Fig. 4, when the base-
line infectivity of F56C/L63P was matched to F56C and 
the parental virus (panel A), the double mutant exhibited 
IDV resistance similar to that observed for F56C alone 
(panel B) indicating that the L63P polymorphism made 
no detectable contribution. Table  2 shows the IC50 lev-
els relative to the parental NL4-3 and a variant encoding 
multiple drug resistance mutations in two independent 
experiments. As noted above, compared to WT, S40A/
F56C tested over a concentration range of 0.01–10  μM 
exhibited no difference in resistance at concentra-
tions above 0.01 μM. The results indicate that the S40A 
WT V S F N F/ P Q I T 
S40A V S F N c/ P Q I T
S40A-L63P V S F N c/ P Q I T 
S40F V S F N F/ P Q I T
S40F-L63P V S F N F/ P Q I T 
+ 0.01 M IDV
0
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b
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UIGA
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UIGA
M
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Fig. 4 Impact of Gagp6 S40A/Pol p6*-PR F56C mutation on IDV susceptibility. 293T cells were co-transfected with DNA encoding the indicated 
construct and a plasmid encoding VSV G protein as described in “Methods”. IDV was present at 0 (a) or 0.01 μM (b). Viral supernatants were collected 
at 48 h post-transfection and serial dilutions were used in triplicate to infect 1 × 104 TZM-bl cells in 96-well plates. Infectivity of the virus particles in 
TZM-bl cells was assessed at 48 h post-infection using the reporter β-galactosidase
Table 2 IC50, IDV, relative change in  IC50 compared 
to NL4-3 susceptibility
IC50 nM WT NL4‑3‑S40A NL4‑3‑S40F NL4‑3 multi‑drug 
resistant strain
Expt 1 1.0 0.94 1.0 20.0
Expt 2 1.0 0.70 0.90 22.6
Page 7 of 14Watanabe et al. Retrovirology  (2016) 13:64 
polymorphism increased resistance to IDV, albeit at low 
drug concentration. This increased resistance most likely 
reflects an impact on PR resulting from the F56C muta-
tion at its N-terminal processing site.
The F56C mutation interferes with mature PR release 
from a model precursor
To investigate the supposition that the Gag p6 S40A/Pol 
p6*-PR F56C mutation impacted PR in a manner that 
changed IDV susceptibility, we determined the effect of 
the F56C mutation on precursor autoprocessing, using 
a model precursor engineered to express in transfected 
mammalian cells. The fusion precursor contains a NL4-
3-derived p6*-PR miniprecursor flanked by L-MBP-
FLAG and HA tags on the N- and C-terminal ends, 
respectively and has been used to study the autoprocess-
ing mechanism [33]. The cleavage site between p6* and 
PR that liberates the mature PR is referred to as the prox-
imal cleavage site in this report and is equivalent to the 
N-terminal cleavage site. There is another cleavage site 
located in the N-terminal region of p6* that is referred 
to as the distal cleavage site in this report. Panel A in 
Fig. 5 shows a schematic drawing of the model precursor 
and expected cleavage products from proximal or distal 
processing. Panel B shows the amino acid sequence at 
the p6*-PR junctions tested in the experiment. GAPDH 
was included as a load control. The precursor contain-
ing the WT F/P cleavage site underwent effective auto-
processing at both the proximal and the distal sites in 
HEK 293T cells, producing two MBP-containing prod-
ucts with residual amount of unprocessed precursor 
(panel C, top, lane 2). The released mature PR was also 
readily detectable (panel 5C, bottom, lane 2). The p6*-PR 
products from distal site processing of the WT precursor 
were not detectable in the absence of any PR inhibitors 
with this system. Our previous studies demonstrate that 
they become detectable in the presence of PIs suggest-
ing that they are formed but rapidly degraded in trans-
fected HEK 293T cells [32, 33, 36] and Figs. 6, 7 below). 
The F56C mutation reduced proximal site processing as 
indicated by reduced amounts of the proximal process-
ing products, L-MBP-Flag-p6* and PR-HA, compared 
to the WT control (panel 5C, lane 3). Distal processing 
still occurred, generating the L-MBP-Flag product and 
a counterpart product, p6*-PR-HAa, which was read-
ily detectable in the lysate (panel 5C, lane 3). We also 
engineered and tested F56 V and F56I precursors in par-
allel as these two mutations are expected to completely 
block proximal processing: a previous sequence analysis 
revealed the absence of β-branched amino acids at the P1 
position of PR substrates [37]. Indeed, these two muta-
tions abolished proximal site processing but had no effect 
Fig. 5 The F56C mutation reduces mature PR release from a model precursor. a, b Schematic drawing showing miniprecursor distal and proximal 
cleavage sites and the F56 mutants tested. c Autoprocessing of L-MBP fusion precursors carrying the indicated mutations. Post-nuclear total lysates 
were resolved on SDS-PAGE and analyzed by Western blotting. Each blot was divided into two parts with 25 kD as the cutoff size and then probed 
separately with mouse Flag and GAPDH (top) or HA (bottom) antibodies. Both blots were probed with IR800 goat anti-mouse secondary antibody 
and scanned using a LI-COR Odyssey scanner. The brackets on the right indicate the autoprocessing products resulted from the proximal (P) and 
distal (D) site cleavages. The images were representative of seven experiments. [Note that the parental NL4-3 employed here encodes SFSF; the parental 
NL4-3 employed in Fig. 3 encodes SFNF, reflecting natural polymorphisms at residue 55]
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on distal processing. Distal processing products, both 
L-MBP-Flag and p6*-PR-HAa, were readily detectable in 
the lysate (panel 5C, lanes 4 and 5). The D25N precur-
sor is auto-processing defective due to the catalytic site 
mutation (panel 5C, lane 6). Taken together, the results 
demonstrate that the F56C mutation interfered with 
proximal site processing leading to reduced production 
of free mature PR-HA. This interference with PR release 
from the precursor provides an explanation for resistance 
to the PR inhibitor exhibited by the variants encoding 
the Gag p6 S40A/Pol p6*-PR F56mutation (c.f., Fig.  4), 
assuming that the model reflects mature PR production 
in the context of viral assembly.
To test the supposition that the F56C mutation influ-
ences with PR autoprocessing in the presence of the 
PR inhibitor, we examined autoprocessing products in 
response to IDV treatment. A typical autoprocessing 
profile of the WT L-MBP precursor is shown in Fig. 6a 
(left). The upper Flag panel shows detection of L-MBP-
Flag-p6* resulting from proximal site processing and 
L-MBP-Flag resulting from distal site processing. These 
processing reactions were not significantly suppressed by 
IDV at concentrations < 15  μM showing that precursor 
autoprocessing was significantly less sensitive than the 
mature PR to inhibition by PR inhibitors. The released 
PR-HA, which is the other product of proximal site pro-
cessing, was readily detectable; its detection gradually 
decreased with increasing concentration of IDV mir-
roring the L-MBP-Flag-p6* profile (Fig. 6, panel B vs. C, 
solid lines). There were two p6*-PR-HA products reactive 
to anti-HA antibody (but not anti-Flag antibody, data 
not shown), referred to as p6*-PR-HAa and p6*-PR-HAb, 
respectively (Fig.  6a, lower HA panel). These two prod-
ucts were not detectable in the absence of PI but became 
detectable at high concentrations of IDV. Possibly, they 
were rapidly degraded in the absence of PR inhibitor 
but accumulated following treatment. Consequently, 
they displayed a bell-shaped detection profile reflecting 
a dynamic balance between production from distal pro-
cessing with rapid degradation at low IDV, then preser-
vation with increasing IDV, followed by loss of detection 
due to suppression of proximal processing at high IDV 
(Fig. 6, panels D and E, solid lines).
The F56C mutation showed several changes com-
pared to the WT control. First, the proximal process-
ing event was reduced as indicated by the fact that the 
Fig. 6 Model precursor autoprocessing in the presence of IDV. a Western blot analysis of the WT (left) and F56C (right) fusion precursors. Post-
nuclear total lysates were resolved by SDS-PAGE and analyzed by Western blotting. Each blot was divided into two parts with 25 kD as the cutoff 
size and then probed separately with mouse Flag and GAPDH (top) or HA (bottom) antibodies. Both blots were probed with IR800 goat anti-mouse 
secondary antibody and scanned using a LI-COR Odyssey scanner. The brackets on the right indicate the autoprocessing products resulted from the 
proximal (P) and distal (D) site cleavages. b–f Quantification of autoprocessing products. The images shown are representative of nine experiments
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corresponding products, L-MBP-Flag-p6* and PR-HA, 
were both reduced compared to the WT control (Fig. 6, 
panels B and C). Meanwhile, the distal processing event 
was not significantly affected or was slightly increased 
at low IDV concentrations, as indicated by L-MBP-Flag 
production (Fig. 6d). Interestingly, one of the distal pro-
cessing products, p6*-PR-HAa, exhibited a profile distinct 
from that released from the WT control (Fig.  6e). This 
p6*-PR-HAa product appeared to resist self-degradation 
and remained at high detection levels with IDV up to 3 
μM, unlike the one released from the WT precursor that 
was self-degraded in the absence of IDV and was only 
detectable at high concentrations of IDV. Thus, the F56C 
mutation altered the detection profile of the p6*-PR-HAa 
product. These data on their own do not rule out the pos-
sibility that mature PR degrades p6*-PR-HAa in trans as 
their detection profiles were inversely correlated. The 
other product, p6*-PR-HAb, displayed a response profile 
similar to the WT control in that it was not detectable 
at low IDV concentrations and became detectable with 
increasing IDV concentrations (Fig.  6f ). Additionally, 
the p6*-PR-HAb released from the F56C mutant precur-
sor appeared to maintain a high level of detection over a 
wider IDV range than that released from the WT control 
(Fig.  6f ). These results support the supposition that the 
F56C mutation altered precursor autoprocessing lead-
ing to release of products with distinct enzymatic activi-
ties in the presence or absence of IDV. Collectively, the 
F56C mutation exerted multifaceted effects including 
(1) decreased production of free mature PR due to sub-
optimal substrate sequence, (2) release of an extended 
PR form (p6*-PR-HAa) that is fairly stable over a wide 
range of IDV (Fig.  6e) and (3) increased detection of 
p6*-PR-HAb.
Trans cleavage by F56C‑related PR products
The precursor PR has intrinsic but limited proteolytic 
activity [38, 39]. The initial production of mature PR 
must be catalyzed by the Gag-Pol precursor itself serving 
as both the substrate and enzyme. Therefore, we designed 
a trans cleavage assay to specifically assess how the pre-
cursor enzymes proteolytically process an engineered 
precursor substrate. The substrate (Myc-M2-PRD25N-V5) 
is a mini-precursor derivative carrying D25N mutation 
making it catalytically inactive, however, it has the WT 
proximal PR cleavage site and thus can be processed by 
a trans acting enzyme to release a PR(D25N)-V5 product 
(Fig. 7a). The amount of the released PR-V5 (band inten-
sity) was quantified to represent trans processing effi-
ciency (Fig. 7b).
Fig. 7 Trans cleavage at the proximal site in the presence of IDV. a Schematic drawing of a model precursor substrate and expected products of 
trans processing by enzymatically active miniprecursors. b, c Quantification of trans processing product and p6*-PRb enzyme. Band intensity was 
used to reflect trans processing efficiency and enzyme detection levels. d–g Western blot analyses of the model substrate and four fusion precur-
sors with increasing IDV. Post-nuclear total lysates were resolved on SDS-PAGE and transferred to a PVDF membrane. Each blot was simultaneously 
probed with mouse HA (top) or rabbit V5 (bottom) antibodies. The blots were then probed with IR800 goat anti-mouse secondary and IR700 goat 
anti-rabbit antibody and scanned using a LI-COR Odyssey scanner. The images shown are representative of four experiments
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We compared four L-MBP fusion precursors as the 
source of trans-acting enzymes in cells co-transfected 
with substrate- and enzyme- encoding plasmids. In 
addition to the full length fusion precursor, at least 
three species of HA-tagged enzymes were detected in 
cell lysates with each showing a different IDV response 
profile (Fig.  7d–g, upper panels). Trans cleavage of the 
substrate was observed with all four L-MBP enzymes, 
as indicated by detection of the 11  kDa PR-V5 product 
(Fig. 7d–g, lower panels). Surprisingly, the WT enzymes 
did not produce the highest level of the PR-V5 prod-
uct, despite the high level of mature PR-HA detected in 
the lysate (Fig.  7d). This observation suggests that the 
mature PR-HA was not effective at trans processing the 
V5-tagged substrate under the test condition. Instead, 
PR-V5 production quantitatively coincides with p6*-
PR-HAb detection signal (Additional file  1: Figure S1), 
suggesting that p6*-PRb might be responsible for trans 
processing the substrate. We were unable to exclusively 
define p6*-PRb as the sole enzyme for substrate trans pro-
cessing due to simultaneous existing/detection of other 
HA antibody reactive enzymes. Possibilities exist that 
p6*-PRb enzyme functions synergistically with PR and/
or p6*-PRa. Another interesting observation was that the 
two F56C-containing constructs released more PR-V5 
products than the WT and F56 V controls and demon-
strated consistently high levels of trans processing prod-
ucts even at micromolar concentrations of IDV (Fig. 7b). 
In contrast, the WT p6*-PR-HAb enzyme appeared to 
be less efficient at trans cleavage despite of its high level 
of detection (Fig.  7c). The F56V control was unable to 
release any mature PR and only produced p6*-PR-HAa 
and p6*-PR-HAb enzymes that demonstrated low level of 
trans processing (Fig. 7g). Thus, the data indicate that the 
p6*-PR-HAb enzyme was enzymatically active at trans 
processing the engineered substrate. Furthermore, the 
p6*-PR-HAb enzyme in the context of F56C content was 
more effective at trans processing than those made by 
the WT or F56  V controls while being resistant to IDV 
suppression. These findings are consistent with a previ-
ous report demonstrating that the p6*-PR fragment can 
process some Gag cleavage sites and many Pol cleavage 
sites in the absence of mature PR [40]. Our results sup-
port the notion that p6*-PR enzymes that remain active 
could prevent ART from suppressing virus replication 
by functionally complementing reduced production and 
activity of mature PR, permitting effective Gag process-
ing and formation of mature infectious viral particles.
Discussion
The retention and conservation of L domain-2, which 
appears to be redundant for the budding function, 
implies that it provides the virus with an evolutionary 
advantage. It should be noted that treatment with ART 
or HAART has been shown to reduce the HIV load more 
effectively and render the viral load undetectable more 
often in the genital tract than in the plasma [41, 42]. 
The women whom we studied were specifically chosen 
because they had detectable HIV in the CVL and plasma 
even though they had a history of ART. Possibly, the L 
domain-2 mutations contributed to the viral loads in 
both compartments, especially the CVL, as suggested by 
the findings for the polymorphism at the S40 site.
In participant #36, variants carrying the S40A muta-
tion were the predominant variants detected in both 
vaginal fluid and plasma at the time of sampling. It is 
possible that the mutation was selected under pressure 
of ART after infection with virus that had S at Gagp6 
position 40 or, alternatively, existed in the region and 
as a virus with the S40A already in it. As the study par-
ticipants were HA/ART-experienced, we hypothesized 
that the selection and maintenance of the mutation pos-
sibly contributed to escape from drug-mediated inhibi-
tion. Sequencing pre- and post- ART samples archived 
from this participant might provide evidence that the 
mutation was selected during ART, thereby supporting 
a relationship. Interestingly, of all the possible nineteen 
other amino acid changes, we found only Ala and Phe 
(S40A and S40F, respectively) as substitutions for the 
Ser40 residue. These residues do not have chemical or 
physical properties in common and one (Ala) altered the 
amino acid sequence in the overlapping pol frame while 
the other did not. In addition, while the substitution of 
F (TT/C) for S (TC/C) requires a pyrimidine to pyrimi-
dine substitution (i.e., a transition), the change from S 
to A (GC/C) that was detected more frequently requires 
a pyrimidine to purine substitution (i.e., a transversion) 
which occurs much less frequently than transitions. We 
therefore hypothesized that the Ser40 to Ala change was 
not random but, rather, was strongly selected.
Our studies indicate that the Gag p6 S40A/Pol p6*-
PR F56C mutation reduces mature PR production but 
enhances production, stability, and activity of extended 
forms of PR. Interestingly, these extended PRs were 
somehow resistant to (at least one) PR inhibitor, IDV 
and one of them (p6*-PRb) can effectively process an 
engineered substrate in trans in a model system. The 
role of p6*-PRa remains undefined at the moment but 
it might provide some fitness advantages of processing 
other cleavages sites in the presence of IDV and reduced 
amounts of mature PR. It should be noted that these 
extended PRs were also observed with the WT con-
trol but at low levels compared to the F56C construct 
(Fig. 6a, the lower panels). This is consistent with previ-
ous reports showing the distal site located in the N-ter-
minal region of p6* as another autoprocessing target [32, 
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33, 36]. Both the proximal and distal sites appear to be 
processed equally in the context of WT fusion precur-
sor. With the F56C mutation, the proximal site process-
ing was suppressed and the distal site processing was 
slightly enhanced (Fig. 6a, the upper panels), which could 
contribute to the enhanced production of extended PRs. 
The fact that IDV was the PR inhibitor on record as pre-
scribed during the period when virus suppression failed 
is highly suggestive that the observations are linked to 
treatment outcome, although caveats related to adher-
ence remain. The reduced production of mature PR 
resulting from the mutation nevertheless permitted for-
mation of infectious particles. This is consistent with 
results obtained in our previous study and herein where 
NL4-3 bearing the S40A mutation produced viral parti-
cles showing normal Gag processing and mature virion 
morphology [22]. We speculate that the extended forms 
of PR could be attributed to this apparent paradox. There 
are at least 10 cleavage sites in the Gag and Gag/Pol poly-
proteins that are recognized and processed by the mature 
PR. Proper processing of these sites is vital to producing 
infectious progeny. The extended forms of PR are capable 
of processing some but not all of the cleavage sites [40]. 
The F56C mutation somehow stabilizes the extended 
forms (both a and b forms) over a wide range of IDV con-
centrations (Fig. 6b). By being resistant to IDV inhibition, 
these enzymes are able to accomplish the “heavy lifting” 
of processing many cleavage sites in the presence of PIs, 
leaving much lower levels of cleavage sites that have to 
be processed by the mature PR. Such a tag-teaming strat-
egy might be used by the virus to achieve ART resistance. 
We noticed that only F56C-containing enzymes demon-
strated enhanced trans processing efficiency while the 
F56 V control showed a much reduced trans processing 
efficiency (Fig. 7b). Therefore, there might be something 
unique about the F56C mutation that not only permits 
it to stabilize the extended PR but also to enhance their 
proteolysis. Consistent with this speculation, a highly 
resistant patient-derived strain also contains the same 
F56C mutation in the proximal cleavage site [43]. It of 
course will require more molecular and structural inves-
tigation to determine how the F56C mutation can regu-
late activities of the extended PRs while conferring drug 
resistance at the same time.
It should be borne in mind that the infectivity assay and 
the assays using model precursors do not test PR inhibi-
tor susceptibility in the same manner. In the infectivity 
assay, the virus is producing both extended and mature 
PR forms. As the drug inhibits both but was optimized 
to target the mature PR, the outcome may mainly reflect 
impact on this form. In contrast, the assay model allows 
detection of the model precursors and uses conditions 
optimized to detect the extended forms. The observed 
reduced production of mature PR due to the F56C muta-
tion compared to the level made by the parental NL4-3 
virus provides an explanation for the mutant’s increased 
IDV resistance: Extended PR forms that are not the 
authentic target of the drug were generated instead of the 
mature PR. It should be noted that although our study 
characterizes the virologic consequences of the S40A 
polymorphism detected in the HIV-1 variants that were 
obtained directly from the WIHS participants, the limita-
tions imposed by the number of subjects examined and 
details of treatment prevent us from drawing direct con-
clusions about the effect of the mutations on susceptibil-
ity to the participant’s treatment. Nevertheless, the S40A 
mutation impacted drug susceptibility. This change in L 
domain-2 could thus influence treatment success or fail-
ure through its influence on viral PR.
A final point is that, in contrast to the S40A mutation 
where much of the viral infectivity was maintained, the 
S40F mutation reduced the infectivity as shown here and 
previously [21, 22] yet the mutation was maintained in 
the infected host quasispecies. This suggests that both 
S40A, which impacts PR, and S40F, which does not, pro-
vide a fitness advantage. A possible explanation for an 
advantage of the S40F mutation might be the formation 
of filopodia-like structures, a phenotype that was exhib-
ited by that mutant [22]. This might support cell-to-cell 
transmission of the virus which might permit escape 
from ART surveillance. We examined this possibility 
and found that, indeed, the infectivity defect of the S40F 
mutant was rescued by cell-to-cell transmission (Addi-
tional file 2: Figure S2). This rescue did not prevent effec-
tive inhibition of virus transmission by IDV.
Conclusion
Changes in HIV’s L domain-2 can significantly alter PR 
function and affect fitness. The alteration of PR activ-
ity can contribute to productive replication in both the 
absence and presence of PR inhibitor.
Methods
Study population
The Women’s Interagency HIV Study (WIHS) is a multi-
center, longitudinal observational cohort study of HIV-1 
infection of women [44]. To compare HIV-1 drug resist-
ance in the plasma and genital tract of women treated 
with antiretroviral agents, we previously analyzed 308 
HIV-1 sequences from 14 women in the Bronx and 
Brooklyn WIHS (described in [26]; GenBank accession 
numbers DQ372126-DQ372434). Three hundred eight 
unique sequences (280 single variants and 28 popula-
tion sequences) encompassed the protease–reverse tran-
scriptase (PR-RT) region of the pol gene. We examined 
the overlapping gag frame of these 308 sequences for L 
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domain-2 mutations and identified such mutations in 7 of 
the 14 subjects. To examine the prevalence of L domain-2 
mutations in a larger group of subjects in the WIHS dur-
ing approximately the same time period, we examined 
population-based sequences of the overlapping gag frame 
from an additional 90 women who exhibited plasma 
viremia after ≥18 consecutive months of ART (Weiser, 
unpublished data). Details of sample collection and analy-
sis; viral RNA isolation, reverse-transcriptase polymerase 
chain reaction (RT-PCR) and sequencing; and genotypic 
drug resistance are described in Kemal et al. [26].
Plasmids and reagents
Plasmids encoding pNL4-3∆Env [45], pNL4-3-S40A or 
pNL4-3-S40F [22], and l-maltose binding protein (MBP)-
FLAG-p6*-PR-HA [33] have been previously described. 
Additional NL4-3 mutants were constructed by site-
directed mutagenesis (Agilent). NL4-3 multiple drug 
resistance (MDR) encodes the following mutations that 
together contribute to high PR and reverse transcriptase 
(RT) drug resistance (PR: 3I, 10I, 33F, 41K, 46I, 54L, 62V, 
63P, 66L, 73A, 77I, 84V, 89M, 90M and 93L; RT: 41L,43E, 
44A,68G,74V, 118F, 165I, 181C, 190S, 203Q, 207D, 
210W, 211K, 214F, 215Y, 219N, 250E). Fusion precur-
sor mutations tested in this study were introduced to the 
L-MBP-Flag-p6*-PR-HA by site-directed mutagenesis as 
previously described [36]. The trans processing substrate, 
Myc-M2-PRD25N-V5, was engineered the same way. In 
this construct, the Myc epitope (EQKLISEEDL) is led by 
a tripeptide (MAS) followed by M2 (a truncated version 
of p6* lacking the N-terminal 20 amino acids as reported 
previously [36]) fused to PR-V5 [32]. All the constructs 
were verified by sequencing analysis.
Fusion precursors and the autoprocessing products 
were detected using antibodies raised against the HA 
tag (H9658, Sigma), the V5 tag (600-401-378, Rock-
land Laboratory) or the FLAG (F1804, Sigma). GAPDH 
levels were detected by using antibody from Millipore 
(MAB374) following manufacturer’s recommendation. 
The diluted primary antibodies were pre-absorbed 
against PVDF membranes coated with cell lysates made 
of mock transfected cells to remove background noise. 
Indinavir (Cat# 8145) was obtained from the AIDS 
Research and Reference Reagent Program, Division of 
AIDS, NIAID, NIH.
ELISA and MAGI assays
The concentration of p24 in the filtered medium was 
determined by ELISA (enzyme-linked immunosorbent 
assay; Immunodiagnostics, Inc.) and equivalent amounts 
of p24 were used to infect MAGI (multinuclear activa-
tion of a β-galactosidase indicator) cells to determine 
infectivity [39].
Infectivity assays
293T cells were co-transfected with pNL4-3∆Env and 
pVSV G. Where indicated, PR inhibitor was added. 
Viral supernatants were collected at 48  h post-transfec-
tion, clarified by centrifugation, and stored at −80  °C. 
Serially diluted viral supernatants were used to infect 
1 ×  104  TZM-bl cells in 96-well plates. Infections were 
done in triplicate with viral supernatants for each con-
struct tested. Infectivity of the virus particles in TZM-
bl cells was assessed at 48  h post-infection using a 
Galacto-Star System for detecting β-galactosidase activ-
ity (Applied Biosystems), as described previously [46, 47].
Electron microscopy
Cells grown on ACLAR film were fixed in 4 % paraform-
aldehyde/0.1 % EM grade glutaraldehyde in PBS, soaked 
in 2  % osmium tetroxide, dehydrated in a graded series 
of ethyl alcohol solutions and embedded in Durpan resin. 
Eighty nm ultrathin sections were counterstained with 
uranyl acetate and lead citrate and viewed with a FEI 
Tecanal BioTwinG2 electron microscope.
Cell culture, transfection, western blots, auto‑processing 
and trans processing assays
HEK293T cells were maintained in DMEM (Dulbecco’s 
Modified Eagle’s Medium; Invitrogen, Carlsbad, CA) cul-
ture media containing penicillin and streptomycin and 
10 % fetal bovine serum as previously described [32, 36]. 
Transfection of HEK293T cells was previously described 
[32, 36]. In brief, cells were seeded onto 6-well, 12-well or 
24-well plates the day before transfection. Cell confluency 
at time of transfection was 40–60  %. The total amount 
of transfected DNA per well was 1  μg (6-well plate), 
0.5 μg (12-well plate), or 0.25 μg (24 well plate). Plasmids 
pcDNA and peGFP (mixed at 19:1) were used as a mock 
transfection control. For trans processing analysis, a DNA 
ratio of enzyme to substrate was consistently maintained 
at 1:1 unless otherwise stated. For a 12-well plate, auto-
claved H2O was added to bring the DNA + H2O volume 
to 65.7 μL. To this, 9.3 μL 2 M CaCl2 and 75 μL 2×  HBS 
(50 mM HEPES, 280 mM NaCl, 10 mM KCl, 12 mM Dex-
trose, 1.5 mM Na2HPO4, pH 7.05) were added drop-wise 
for a total volume of 150 μL. The mixture was then added 
to plated cells and incubated for 7–11 h before the media 
was changed. For experiments involving drug treatment, 
drug was added at this point to the desired concentra-
tion. At 24–30  h post transfection, cells were washed 
with PBS once and lysed with 80 μL Lysis Buffer/PI solu-
tion (Lysis Buffer A: 25 mM Tris–HCl pH 8.0, 150 mM 
NaCl, 1  % sodium deoxycholate, 1  % Triton X-100 plus 
1× PI cocktail). Cell debris was removed and lysate was 
transferred to a microcentrifuge tube containing 15  μL 
6× SDS Loading Buffer (60  % glycerol, 0.6  M DTT 
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powder, 6  % SDS, 0.006  % Bromophenol blue, 0.35  M 
Tris–HCl, water). Samples were boiled for 3–5  min, 
resolved by 13  % SDS-PAGE, and transferred onto a 
PVDF membrane (Millipore 0.45 µ Immobilon P). Fluo-
rescently labeled secondary antibodies IR800 goat anti-
mouse (Li-COR cat#926-32210), IR700 goat anti-mouse 
(Li-COR cat#926-68020), and IR800 goat anti-rabbit (Li-
COR cat#926-32211) were used to visualize Western blot 
images by an Odyssey infrared dual laser scanning unit 
(LI-COR Biotechnology, Lincoln, Nebraska). ImageStu-
dio® quantification program (Li-COR Biotechnology) 
was used to determine signal intensity for a given band 
by measuring the total value of the band area minus local 
background noise times band area. Trans processing effi-
ciency was reflected by PR-V5 intensity.
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